Basis of Presentation and Significant Accounting Policies - Schedule of segment reporting (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2025	Mar. 31, 2024
Research and development
General and administrative		$ 3,965	$ 3,858
Restructuring charges	$ 3,400	3,375	0
Net loss		(14,211)	(10,707)
Reconciliation of segment net loss
Net loss		$ (14,211)	$ (10,707)
Other segment Item description		(a) Other segment items in segment net loss includes other income (expense), net and income tax expense.	(a) Other segment items in segment net loss includes other income (expense), net and income tax expense.
Single reportable segment
Research and development
Net loss		$ (14,211)	$ (10,707)
Reconciliation of segment net loss
Net loss		(14,211)	(10,707)
Single reportable segment | Operating segments
Research and development
EO-3021 clinical program		3,410	2,758
Seribantumab clinical program		60	1,066
Discovery, preclinical, and other unallocated research and development expense		1,425	143
Personnel expenses (including stock-based compensation)		1,981	2,044
General and administrative		3,965	3,858
Restructuring charges		3,375	0
Other segment items		(5)	838
Net loss		(14,211)	(10,707)
Reconciliation of segment net loss
Net loss		(14,211)	(10,707)
Single reportable segment | Adjustments and reconciling items
Research and development
Other segment items		$ 0	$ 0